<http://model.geneontology.org/R-HSA-9734091>
        a       <http://www.w3.org/2002/07/owl#Ontology> ;
        <http://www.w3.org/2000/01/rdf-schema#comment>
                "For logical inference, import the integrated tbox ontology http://purl.obolibrary.org/obo/go/extensions/go-lego-reacto.owl" , "Imported from Reactome: https://reactome.org/content/detail/R-HSA-9734091" , "http://www.reactome.org" ;
        <http://geneontology.org/lego/modelstate>
                "development" ;
        <http://purl.org/dc/elements/1.1/contributor>
                "GOC:reactome_curators" ;
        <http://purl.org/dc/elements/1.1/date>
                "2024-05-16" ;
        <http://purl.org/dc/elements/1.1/title>
                "Drug-mediated inhibition of MET activation - imported from: Reactome" ;
        <http://purl.org/pav/providedBy>
                "https://reactome.org" ;
        <https://w3id.org/biolink/vocab/in_taxon>
                <http://purl.obolibrary.org/obo/NCBITaxon_9606> .

<http://purl.org/dc/elements/1.1/title>
        a       <http://www.w3.org/2002/07/owl#AnnotationProperty> .

<https://w3id.org/biolink/vocab/in_taxon>
        a       <http://www.w3.org/2002/07/owl#AnnotationProperty> .

<http://purl.obolibrary.org/obo/GO_0008150>
        a       <http://www.w3.org/2002/07/owl#Class> .

<http://www.w3.org/2004/02/skos/core#narrower>
        a       <http://www.w3.org/2002/07/owl#AnnotationProperty> .

<http://purl.org/dc/elements/1.1/date>
        a       <http://www.w3.org/2002/07/owl#AnnotationProperty> .

<http://purl.org/dc/elements/1.1/contributor>
        a       <http://www.w3.org/2002/07/owl#AnnotationProperty> .

<http://www.geneontology.org/formats/oboInOwl#hasDbXref>
        a       <http://www.w3.org/2002/07/owl#AnnotationProperty> .

<http://www.w3.org/2004/02/skos/core#note>
        a       <http://www.w3.org/2002/07/owl#AnnotationProperty> .

<http://model.geneontology.org/R-HSA-9734091/R-HSA-9734091>
        a       <http://www.w3.org/2002/07/owl#NamedIndividual> , <http://purl.obolibrary.org/obo/GO_0008150> ;
        <http://www.w3.org/2000/01/rdf-schema#comment>
                "MET receptor tyrosine kinase (RTK) is a proto-oncogene that is frequently aberrantly activated in cancer through gene amplification and/or activating mutations that result in hypersensitivity to HGF stimulation or HGF-independent activation. Oncogenic MET activation can occur as a primary mechanism of malignant transformation or be selected secondarily, as a mechanism of resistance to therapeutics that target related RTKs, such as EGFR. MET targeted anti-cancer therapeutics, either recombinant monoclonal antibodies (MAbs) or small tyrosine kinase inhibitors (TKIs), have shown promise as a first-line agents for the treatment of solid tumors with primary MET activation or as second-line agents for the treatment of solid tumors with acquired MET-mediated resistance to other RTK-targeted therapies (reviewed in Comoglio et al. 2018)." ;
        <http://www.w3.org/2000/01/rdf-schema#label>
                "Drug-mediated inhibition of MET activation" ;
        <http://purl.org/dc/elements/1.1/contributor>
                "GOC:reactome_curators" , "Edited: Orlic-Milacic, Marija, 2021-08-10" , "Authored: Orlic-Milacic, Marija, 2021-06-15" , "Reviewed: Kadambat Nair, Sisira, 2021-08-05" ;
        <http://purl.org/dc/elements/1.1/date>
                "2024-05-16" ;
        <http://purl.org/pav/providedBy>
                "https://reactome.org" ;
        <http://www.geneontology.org/formats/oboInOwl#hasDbXref>
                "R-HSA-9734091" ;
        <http://www.w3.org/2004/02/skos/core#narrower>
                <http://model.geneontology.org/R-HSA-6807004/R-HSA-6807004> ;
        <http://www.w3.org/2004/02/skos/core#note>
                "org.biopax.paxtools.model.level3.Pathway" .

<http://purl.org/pav/providedBy>
        a       <http://www.w3.org/2002/07/owl#AnnotationProperty> .

<http://geneontology.org/lego/modelstate>
        a       <http://www.w3.org/2002/07/owl#AnnotationProperty> .
